Drug intelligence / Profile preview

uv-killed bacillus coagulans hammer

Development stage: Preclinical
Modality: Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics

Overview

UV-killed Bacillus coagulans Hammer is an inactivated bacterial preparation being investigated in preclinical studies for its potential anticancer effects. This biologic consists of the probiotic bacterial strain Bacillus coagulans Hammer that has been inactivated using ultraviolet light. In vitro research has demonstrated that the compound can induce apoptosis in human colorectal cancer cell lines by targeting apoptotic pathways. Specifically, it has been shown to decrease the expression of the antiapoptotic protein Bcl-2 and increase the expression of the proapoptotic protein Bax. It is currently an early-stage research compound studied in academic settings and does not appear to be associated with a specific company or clinical development program.

Other names: UV-inactivated Bacillus coagulans Hammer

Targets

BAX (Apoptosis regulator BAX)

Beyond the preview

Go deeper on uv-killed bacillus coagulans hammer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on uv-killed bacillus coagulans hammer.

Explore the full profile